Compare HOFT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | CHRS |
|---|---|---|
| Founded | 1924 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.4M | 177.7M |
| IPO Year | 1999 | 2014 |
| Metric | HOFT | CHRS |
|---|---|---|
| Price | $13.41 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 35.9K | ★ 1.2M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $278,139,000.00 | N/A |
| Revenue This Year | $17.37 | $73.08 |
| Revenue Next Year | $9.00 | $30.94 |
| P/E Ratio | $134.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.62 | $1.09 |
| 52 Week High | $18.09 | $2.62 |
| Indicator | HOFT | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 37.58 | 55.04 |
| Support Level | $11.99 | $1.34 |
| Resistance Level | $13.63 | $1.46 |
| Average True Range (ATR) | 0.54 | 0.09 |
| MACD | -0.13 | 0.03 |
| Stochastic Oscillator | 5.56 | 85.71 |
Hooker Furnishings Corp is a designer, marketer, and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality, and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segments: Hooker Branded segment, Domestic Upholstery segment, and All Other. It generates the majority of its revenue from the Hooker Branded segment.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.